Healthpeak Properties, Inc. (DOC) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Healthpeak Properties, Inc. is a Maryland corporation organized as a Real Estate Investment Trust (REIT) and an Umbrella Partnership REIT (UPREIT). The company owns, operates, and develops high-quality healthcare real estate across three reportable segments: Outpatient Medical, Lab, and Continuing Care Retirement Community (CCRC). The company completed its merger with Physicians Realty Trust on March 1, 2024.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $705.9 million | $700.4 million | $2,103.1 million | $2,002.5 million |
| Net Income (Loss) Applicable to Common Shares | $(117.3) million | $85.7 million | $(43.3) million | $238.0 million |
| Net Income (Loss) Per Share (Diluted) | $(0.17) | $0.12 | $(0.06) | $0.36 |
| Adjusted NOI (Total Portfolio) | $375.0 million | $378.8 million | $1,141.2 million | $1,095.8 million |
| Nareit FFO (Diluted) | $322.7 million | $315.8 million | $954.2 million | $797.5 million |
| AFFO (Diluted) | $296.5 million | $300.6 million | $917.7 million | $845.0 million |
| Total Debt Outstanding | $9.13 billion | $8.72 billion | $9.13 billion | $8.72 billion |
| Cash and Cash Equivalents | $91.0 million | $119.8 million | $91.0 million | $119.8 million |
| Operating Cash Flow (YTD) | $957.9 million | $787.0 million | $957.9 million | $787.0 million |
Material Changes vs. Prior Period
- Net Loss vs. Net Income: The company reported a net loss of $117.3 million for Q3 2025 compared to net income of $85.7 million in Q3 2024. This decline was primarily driven by $176.3 million in equity losses from unconsolidated joint ventures due to other-than-temporary impairment charges on lab assets (South San Francisco JVs and Needham Land Parcel JV).
- Gain on Sales: Gains on sales of real estate decreased significantly to $11.5 million in Q3 2025 from $62.3 million in Q3 2024, reflecting fewer dispositions in the current period.
- Interest Expense: Interest expense increased to $76.8 million in Q3 2025 from $74.1 million in Q3 2024, attributed to new senior unsecured note issuances ($1 billion total in 2025) and higher commercial paper borrowings, partially offset by the repayment of lower-coupon debt.
- Segment Performance:
- Outpatient Medical: Adjusted NOI increased 2.0% (Same-Store) and 1.5% (Total Portfolio) due to lease renewals and rent escalations.
- Lab: Adjusted NOI decreased 3.2% (Same-Store) and 6.8% (Total Portfolio) primarily due to lower occupancy rates.
- CCRC: Adjusted NOI increased 9.4% (Same-Store) and 10.0% (Total Portfolio) driven by higher resident fees and occupancy.
Guidance, Outlook, and Risks
- Dividends: The Board declared a monthly common stock cash dividend of $0.10167 per share for October, November, and December 2025. The company transitioned to a monthly dividend payment schedule in April 2025.
- Capital Allocation: The company repurchased 5.09 million shares for $94 million during the first nine months of 2025. Approximately $406 million remains available under the 2024 Share Repurchase Program. The company also has $1.5 billion available under its At-The-Market (ATM) equity offering program.
- Development: Development and redevelopment commitments decreased to $256 million as of September 30, 2025. Several projects were placed in service during the period, including outpatient medical and lab developments.
- Risks and Contingencies:
- Impairment Risk: Significant impairment charges were recognized on unconsolidated joint ventures due to depressed biotechnology capital raising, lower market rents, and oversupply in the life science sector.
- Interest Rate Risk: While approximately 95% of consolidated debt is fixed-rate, the company remains exposed to variable rate debt (commercial paper and certain mortgage debt). A 1% increase in interest rates would increase annual interest expense by approximately $5 million.
- Tenant Concentration: CommonSpirit Health represented 3% of total revenues in Q3 2025.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the discounted cash flow models for the $176 million impairment charge on unconsolidated joint ventures (South San Francisco JVs and Needham Land Parcel JV).
- Debt Maturities: Review the debt maturity schedule, noting $995 million in maturities in 2026 and $1.35 billion in 2027, to assess refinancing needs.
- Lab Occupancy Trends: Monitor the Lab segment's occupancy rate (93.4% at period end) and the impact of redevelopment projects on future revenue.
- Merger Integration: Assess the realization of merger synergies, evidenced by the decrease in transaction and merger-related costs from $122 million (YTD 2024) to $18 million (YTD 2025).
- CCRC Entrance Fees: Review the collection of non-refundable entrance fees ($108 million YTD 2025) versus amortization to understand cash flow timing in the CCRC segment.